85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and Drug Administration (FDA) by year end Interim analysis requested by FDA demonstrated statistically significant ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Sign up to receive free daily think pieces from leading analysts or our weekly digest, that includes our editorial and a collection of recent articles in brief.

Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...